Vaxxinity

Update in progress

VAXX (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vaxxinity, Inc. is a Merritt Island, Florida-based biotechnology company developing therapies for neurology, cardiovascular health, and Covid-19. Its pipeline includes UB-311 (phase 2) targeting toxic amyloid-beta for Alzheimer’s, UB-312 (phase 1) targeting toxic alpha-synuclein for Parkinson’s and other synucleinopathies, and VXX-301 (preclinical) an anti-tau candidate. It also advances VXX-401 (phase 1) to lower LDL-C by targeting PCSK9, UB-313 for migraines, and UB-612 for SARS-CoV-2 in phase 3.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive